| Literature DB >> 14999774 |
Viviana Gismondi1, Maurizio Meta, Luigina Bonelli, Paolo Radice, Paola Sala, Lucio Bertario, Alessandra Viel, Mara Fornasarig, Arrigo Arrigoni, Mattia Gentile, Maurizio Ponz de Leon, Luca Anselmi, Cristina Mareni, Paolo Bruzzi, Liliana Varesco.
Abstract
Biallelic germline mutations in the base excision repair gene MYH have been reported in patients with multiple colorectal adenomas and cancer and in sporadic FAP patients not showing a detectable APC germline mutation. In this study, the prevalence of the common Y165C and G382D germline variants of the MYH gene was examined in 70 FAP/AAPC patients with no detectable APC mutation and a family history compatible with recessive inheritance. In addition, 141 normal-population adenoma patients (mean number of adenomas, 2.8; range, 1-9) and 52 clean colon controls were studied. The entire coding region of the MYH gene was analyzed in Y165C or G382D heterozygous patients. Since the same second mutational event (a 3 bp deletion in exon 14, 1395delGGA) was detected in 3 patients, the prevalence of this variant was also examined in all groups. In all, 14 of 70 patients in the FAP/AAPC group (20%; 95% CI = 11.7-31.6%) had biallelic germline MYH variants and 3 were heterozygotes (4.3%). None of the 141 normal-population adenoma patients carried biallelic germline MYH variants (95% CI = 0.06-4.1%) and 3 were heterozygotes (2.1%). In the control group, no MYH variants were detected. These results indicated that MYH-associated polyposis (MAP) is present in about 20% of Italian FAP/AAPC patients, in whom no germline APC mutation is detectable and showing a family history compatible with recessive inheritance, and in a small fraction of patients with colorectal adenomas in the general population. In addition, our data suggest that mutation 1395delGGA is a subpolymorphic MYH mutational event in some Caucasian populations. Copyright 2004 Wiley-Liss, Inc.Entities:
Mesh:
Substances:
Year: 2004 PMID: 14999774 DOI: 10.1002/ijc.20054
Source DB: PubMed Journal: Int J Cancer ISSN: 0020-7136 Impact factor: 7.396